FDA Warns of Dosing Errors and Adverse Events Linked to Compounded GLP-1 Receptor Agonists

FDA Warns of Dosing Errors and Adverse Events Linked to Compounded GLP-1 Receptor Agonists

The FDA has updated its safety communication on compounded semaglutide, a GLP-1 receptor agonist, citing reports of adverse events including hospitalizations linked to dosing errors, bacterial contamination, and incorrect drug concentrations. The agency also highlighted that some compounded products contain salt forms of the active ingredient, such as semaglutide acetate or semaglutide sodium, which differ from the base compound used in FDA-approved medications and have not been shown to be safe or effective for the same indications.

With the FDA’s determination that certain semaglutide injections are no longer in shortage, the regulatory allowances that previously permitted large-scale compounding of unapproved copies under Sections 503A and 503B no longer apply. The update underscores differences in oversight between approved products that completed full pre-market review and compounded versions that bypass those requirements. [1][2]

Adverse Events Linked to Compounded Products

The FDA has received adverse event reports associated with compounded semaglutide. These include cases of hospitalization stemming from dosing errors when patients used multi-dose vials, as well as instances of bacterial contamination and products containing incorrect concentrations. [1]

Such reports illustrate how variations in compounding practices can introduce risks not typically seen with standardized, approved formulations.

Differences in Formulation and Regulatory Oversight

Compounded semaglutide products may contain semaglutide salts rather than the base form of the molecule used in approved drugs. The FDA has stated that these salt versions have not been evaluated for safety or effectiveness in the same manner. [2]

Approved GLP-1 receptor agonists undergo rigorous review for quality, potency, and purity before reaching patients. Compounded drugs, by contrast, are not subject to the same pre-market approval process, which the agency notes can lead to inconsistencies in strength and composition. [1][3]

Resolution of Shortage Status

On May 29, 2024, the FDA determined that certain semaglutide injections no longer meet the criteria for a drug shortage. This regulatory finding removes the previous flexibility that allowed compounding pharmacies to produce large volumes of unapproved copies under federal provisions. [1]

The European Medicines Agency’s separate scientific review of semaglutide similarly emphasized the importance of using products that have met established regulatory standards for safety and quality. [3]

What this means

The reports associate compounded GLP-1 receptor agonists with specific safety signals, including dosing mistakes and contamination, that have resulted in serious outcomes in some documented cases. The distinction between FDA-approved products and compounded versions centers on the level of pre-market evaluation and manufacturing controls. As shortage determinations evolve, the regulatory framework limits the production of unapproved copies, highlighting ongoing differences in how these products reach patients.

Limitations

Adverse event reports are voluntary and likely represent an undercount of total incidents. Data and enforcement actions are limited to the United States regulatory framework. Compounding pharmacy practices and product quality can vary widely, making generalization difficult. Regulatory status of shortages can change; current information must be verified directly on FDA.gov.